Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -417.17% as of the fiscal period ended Thursday, December 31, 2020.
Limited history available
ENLV EBITDA Margin has fewer than three reported periods, so a trend chart would be misleading.
EBITDA MARGIN
-417.17%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Enlivex Therapeutics Ltd.
Market Cap
$5.93M
EBITDA Margin
-417.17%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.91M
EBITDA Margin
-3649.83%
TTM Avg
-7184.74%
3Y Avg
-3660.35%
5Y Avg
-2451.26%
Market Cap
$5.85M
EBITDA Margin
-314.07%
TTM Avg
-394.57%
3Y Avg
-554.22%
5Y Avg
-637.29%
Market Cap
$5.98M
EBITDA Margin
-41051.94%
TTM Avg
-32118.88%
3Y Avg
-145781.05%
5Y Avg
-130042.11%
Market Cap
$5.60M
EBITDA Margin
-23296.89%
TTM Avg
-13717.94%
3Y Avg
-7355.60%
5Y Avg
-5953.70%
Market Cap
$5.66M
EBITDA Margin
-9081.41%
TTM Avg
-6199.48%
3Y Avg
-3862.58%
5Y Avg
-3269.64%
Market Cap
$6.24M
EBITDA Margin
-729.87%
TTM Avg
-884.05%
3Y Avg
-981.20%
5Y Avg
-851.95%
Market Cap
$6.40M
EBITDA Margin
-110.02%
TTM Avg
-99.60%
3Y Avg
-109.65%
5Y Avg
-93.07%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enlivex Therapeutics Ltd. (ENLV) | $5.93M | -417.17% | N/A | N/A | N/A |
| Scienture Holdings, Inc. (SCNX)vs › | $5.91M | -3649.83% | -7184.74% | -3660.35% | -2451.26% |
| Lucyd, Inc (LUCY)vs › | $5.85M | -314.07% | -394.57% | -554.22% | -637.29% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | -41051.94% | -32118.88% | -145781.05% | -130042.11% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.72M | N/A | N/A | N/A | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.60M | -23296.89% | -13717.94% | -7355.60% | -5953.70% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.66M | -9081.41% | -6199.48% | -3862.58% | -3269.64% |
| Femasys Inc. (FEMY)vs › | $6.24M | -729.87% | -884.05% | -981.20% | -851.95% |
| Biomerica, Inc. (BMRA)vs › | $6.40M | -110.02% | -99.60% | -109.65% | -93.07% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.43M | -485.73% | -485.73% | -485.73% | -485.73% |
Gross Margin
0.0%
EBITDA Margin
-417.2%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2020-12-31 | -417.17% |
